Santen Announces The Initiation Of A Multinational Phase III Program Evaluating Sirolimus (DE-109) For The Treatment Of Non Infectious Posterior Uveitis
Santen Inc., announced the initiation of a global Phase 3 clinical study evaluating its investigational drug sirolimus (DE‐109) for the treatment of noninfectious posterior uveitis.